Edesa Biotech Announces Proposed Public Offering
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has commenced an underwritten public offering of its common shares (or pre-funded warrants to purchase common shares in lieu thereof) and…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
